Liquidia Q2 revenue jumps on YUTREPIA sales

Liquidia

12/08/2026 11:39

Overview
U.S. biopharma firm's Q2 sales revenue rose sharply on YUTREPIA sales
EPS for Q2 met analyst expectations
Company posted fourth consecutive quarter of profitability

Outlook
Company did not provide specific financial guidance for upcoming quarters or the full year

Result Drivers
YUTREPIA SALES GROWTH - Co said higher sales volume of YUTREPIA drove revenue increase in Q2
PATIENT ADOPTION - Co reported about 5,900 unique patient prescriptions and more than 5,000 patients treated since YUTREPIA launch
EXPANDED PRESCRIBER BASE - Co said number of prescribers exceeded 1,100 since launch, with over 30% prescribing to at least 5 patients

Company press release: ID:nGNXvnPw2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$171.68 mln
 
Q2 EPS
Meet
$0.74
$0.74 (8 Analysts)
Q2 Net Income
 
$74.72 mln
 
Q2 Operating Income
 
$85.52 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Liquidia Corporation is $76.88, about 12.7% below its August 11 closing price of $88.05
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads
Aug 10 - Tonix Q2 revenue rises sharply on TONMYA launch
Aug 10 - BridgeBio Pharma's Q2 revenue beats on higher Attruby sales
Aug 10 - Axsome Therapeutics Q2 revenue rises on AUVELITY  growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)